Agenus Inc. Stock News

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the

Shares of Agenus are way down this year, but the cancer drug developer still has some interesting assets. An experimental cancer therapy that just started phase 2 trials could generate more than $1 bi

Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target

Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Results Conference Call March 14, 2024 8:30 AM ET

The clinical-stage biotech wants to push its share price well above the current minimum requirement. It is currently well under the mandated $1 per share level.

Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.

Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment. The combination demonstrated sig

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Small-cap stocks took the brunt of the 2022 bear market and many names have yet to recover. Agenus and Coherus BioSciences are prime examples.

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.

The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference. If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize.